DNA minor groove binding ligands: a new class of anticancer agents

Bibliography

• PEZZONI G, GRANDI M, BIASOLI Get aL: Biological profile of FCE 24517, a novel benzoyl mustard analogue of Distamycin A. Br. J. Cancer (1991) 64:1047-1050. The paper presents evidence that Tallimustine is an active antitumour agent in vivo in preclinical systems.
   Google Scholar
• HOUGHTON PJ, CHESHIRE PJ, HALLMAN JD, HOUGHTON
   Google Scholar
• •JA: Therapeutic efficacy of the cyclopropylpyrroloin-dole, carzelesin, against xenografts derived from adult and childhood solidturnors. Cancer Chem other. Pharma-col. (1995) 36:45-52. The paper presents evidence that Carzelesin is an active antitumour agent in vivo in preclinical systems.
   Google Scholar
• LI LH, DEKONING TF, KELLY RC et aL: Cytotoxicity andantitumour activity of carzeles in, a prodrug cyclo-propylpyrroloindole analogue. Cancer Res. (1992) 52:4904-4913. The paper presents evidence that Carzelesin is an active antitumour agent in vivo in preclinical systems.
   Google Scholar
• MARTIN DG, BILES C, GERPHEIDE SA et aL: CC-1065 (NSC 298223), a potent new antitumour agent improved production and isolation, characterization and antitu-mor activity. J. Ant/blot. Tokyo (1981) 34:1119–1125.
   PubMed Web of Science ®Google Scholar
• CHEN AY, YU C, GATTO B, LIU LF: DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA (1993) 90:8131–8135.
   PubMed Web of Science ®Google Scholar
• BROGGINI M, ERBA E, PONTI M et al: Selective DNA interaction of the novel Distamycin derivAive FCE 24517. Cancer Res. (1991) 51:199-204. The paper provides evidence of a selective alkylation of N3 adenines of Tallimustine by a mechanism similar to that previously observed for CC–1065.
   Google Scholar
• BROGGINI M, PONTI M, OTTOLENGHI S et al.: Dista mydm inhibit the binding of OTF-1 and NFE-1 tra ns factorsto their conserved DNA elements. Nucleic Acids Res. (1989) 17:1051-1059. The paper provides the first piece of evidence that a DNA binding drug like Distamycin can act by selectively blocking the binding of transcription factors to DNA.
   Google Scholar
• DORN A, AFFOLTER M, MULLER M, GEHRING WJ, LEUPIN
   Google Scholar
• •W: Distamycin-induced inhibition of homeedomain-DNA complexes. EMBO J. (1992) 11:279-286. The paper confirms the previous finding by Broggini using for the first time purified transcription factors instead of cell nuclear extracts.
   Google Scholar
• BELLORINI M, MONCOLLIN V, DINCALCI M, MONGELLI N, MANTOVANI R: Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res. (1995) 23:1657–1663.
   PubMed Web of Science ®Google Scholar
• CHIANG SY, WELCH J, RAUSCHER FJ, BEERMAN TA: Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Bio-chemistry (1994) 33:7033–7040.
   Google Scholar
• HURLEY LH, REYNOLDS VL, SWENSON DH, PETZOLD GL, •SCAHILL TA: Reaction of the antitumour antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science (1984) 226:843-844. The paper provides the demonstration that CC-1065 binds in the minor groove of DNA alkylating adenine at the N3 position. This mechanism will be later shown for CC-1065 analogues and for Distamycin derivatives containing an alkylating moiety.
   Google Scholar
• HURLEY LH, SUN D: (+)-CC-1065 as a probe for intrinsic and protein-induced bending of DNA. J. MoL Recognit. (1994) 7:123–132.
   PubMedGoogle Scholar
• SUN D, HURLEY LH: Co-operative bending of the 21-base - pair repeats of the SV40 viral early promoter by human Spl. Biochemistry (1994) 33:9578–9587.
   PubMed Web of Science ®Google Scholar
• MCHUGH MM, WOYNAROWSKI JM, MITCHELL MA et al.: CC-1065 bonding to intracellular and purified SV40 DNA: site specificity and functional effects. Biochemistry (1994) 33:9158–9168.
   PubMed Web of Science ®Google Scholar
• LEE CS, PFEIFER GP, GIBSON NW: Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry (1994) 33:6024–6030.
   PubMed Web of Science ®Google Scholar
• BROGGINI M, COLEY HM, MONGELLI N et al.: DNA se-quence-specific adenine alkylation by the novel antitu-mour drug tallimustine (FCE24517), a benzoyl nitrogen mustard derivative of Distamycin. Nucleic Adds Res. (1995) 23:81–87.
   PubMed Web of Science ®Google Scholar
• WYATT MD, LEE M, GARBIRAS BJ, SOUHAMI RL, HARTLEY
   Google Scholar
• •JA: Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of Distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. Bio-chemistry (1995) 34:13034-13041. The paper provides evidence that the cytotoxic potency of Tal-limustine is related to the DNA sequence specific alkylations.
   Google Scholar
• BECCAGLIA P, GRIMALDI KA, HARTLEY JA et al: DNA adduct formation of the sequence selective cytotoxicagent tallimustine resolved at the nucleotide level in a single copy gene in mammalian cells [Abstract]. Br. J. Cancer (1996) 73 (Supp XXVI):12. The paper shows that the high DNA sequence specificity of alkyla-tion of Tallimustine observed in vitro is confirmed in intact cells exposed to cytotoxic drug concentrations.
   Google Scholar
• DAMIA G, IMPERATORI L, CITTI L, MARIANI L, DINCALCI M: 3-methyladenine-DNA-glycosylase and 06-alkyl gua-nine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Br. J. Cancer (1996) 73:861–865.
   PubMed Web of Science ®Google Scholar
• IMPERATORI L, DAMIA G, TAVERNA P et al: 3T3 NIH murine fibroblasts and B78 murine mdanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents. Carcinogenesis (1994) 15:533–537.
   PubMed Web of Science ®Google Scholar
• DAMIA G, IMPERATORI L, STEFANINI M, DINCALCI M:
   Google Scholar
• •Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anticancer agents. Int. J. Cancer (1996) 66:779-783. The paper indicates that cells deficient in specific proteins involved in nucleotide excision repair mechanisms confer a much greater sensitivity to conventional alkylating agents, but only a small increase in the sensitivity to DNA minor groove alkylators, implying that other mechanisms are implicated in the repair of the DNA lesions caused by these drugs.
   Google Scholar
• TANG M, QIAN M, PAO A: Formation and repair of antitumour antibiotic CC-1065-induced DNA adducts in the adenine phosphoribozyltransferase and amplified dihydrofolate reductase genes of Chinese hamster ovary cells. Biochemistry (1994) 33:2726–2732.
   PubMedGoogle Scholar
• COLELLA G, BONFANTI M, DINCALCI M, BROGGINI M:
   Google Scholar
• •Characterization of a protein recognizing minor groove binders-damaged DNA. Nucleic Acids Res. (1996) 24:4227-4233. The paper provides evidence that there are proteins which recognise the binding of minor groove ligands to A-T rich DNA sequence.
   Google Scholar
• NGUYEN HN, SEVIN BU, AVERETTE H et al.: Spectrum ofcell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity. J. Cancer Res. din. Oncol. (1992) 118:515–522.
   PubMed Web of Science ®Google Scholar
• BHUYAN BK, SMITH KS, ADAMS EG et al.: Adozelesin, apotent new alkylating agent: cell-killing kinetics and cell-cycle effects. Cancer Chemother. Pharmacol. (1992) 30:348–354.
   PubMed Web of Science ®Google Scholar
• ERBA E, MASCELLANI E, PIFFERI A, DINCALCI M: Compari-
   Google Scholar
• ?son of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by Mel-phalan in the 5W626 cell line. InL J. Cancer (1995) 62:170-175. The paper indicates that the cell cycle perturbations of a nitrogen mustard which binds in the DNA minor groove are different from those nitrogen mustards which bind in the DNA major groove.
   Google Scholar
• GRANIELA SIR EA, VIKHANSKAYA F, BROGGINI M: Sensi-tivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann. Oncol (1995) 6:589–593.
   PubMed Web of Science ®Google Scholar
• P0 POLO L, VIGANO F, ERBA E, MON GELLI N, DINCALCI
   Google Scholar
• •M: Effects of a novel DNA-damaging agent on the bud- ding yeast Saccharomyces cerevisiae cell cycle. Yeast (1996) 12:349-359. The paper provides evidence that the absence of a G2 check-point like rad 9 causes a dramatic increase in the sensitivity to Saccharomy-ces cerevisiae to a DNA minor groove alkylator such as Tallimustine.
   Google Scholar
• ZSIDO TJ, BEERMAN TA, MEEGANRL, WOYNAROWSKI JM, BAKER RM: Resistance of CHO cells expressing P-glyco-protein to cyclopropylpyrroloindole (CPI) alkylating agents. Biochem. Pharmacol. (1992) 43:1817–1822.
   PubMed Web of Science ®Google Scholar
• MOY BC, PETZOLD GL, BADINER GJ et aL: Charac-terization of B16 melanoma cells :resistant to the CC-1065 analogue U-71,184. Cancer Res. (1990) 50:2485–2492.
   PubMed Web of Science ®Google Scholar
• GERONI C, PESENTI E, TAGLIABUE G et al.: Establishment of L1210 leukemia cells resistant to the Distamycin-A derivative (FCE 24517): characterization and cross-re-sistance studies. Int. J. Cancer (1993) 53:308–314.
   PubMed Web of Science ®Google Scholar
• CAPOLONGO L, MELEGARO G, BROGGINI M, MONGELLIN, GRANDI M: Characterisation of a LoVo subline resis-tant to a benzoyl mustard derivative of Distamycin A (FCE 24517). Br. J. Cancer (1993) 68:916–919.
   PubMed Web of Science ®Google Scholar
• CIOMEI M, PASTORI W, CAPOLONGO L et al: Decreasedtyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine). Br. J. Cancer (1995) 72:1504–1508.
   PubMed Web of Science ®Google Scholar
• SMITH KS, FOLZ BA, ADAMS EG, BHUYAN BK: Synergisticand additive combinations of several antitumour drugs and other agents with the potent alkylating agent adozelesin. Cancer Chem other. PharmacoL (1995) 35:471–482.
   PubMedGoogle Scholar
• COTE S, MOMPARLER RL: Evaluation of the antineoplas-tic activity of adozele sin alone and in combination with 5-aza-2'-deoxycytidine and cytosine anbinoside on DLD-1 human colon carcinoma cells. Anticancer Drugs (1993) 4:327–333.
   PubMed Web of Science ®Google Scholar
• TAGLIABUE G, FILIPPINI C, UBEZIO P, D'INCALCI M:Combination of the minor groove alkylator tal-limustine and Melphalan. Eur. J. Cancer (1997) 33:284–287.
   PubMed Web of Science ®Google Scholar
• FLEMING GF, RATAINMJ, O'BRIEN SM et al: Phase I study of adozelesin administered by 24-hour continuous in- travenous infusion. J. Natt Cancer Inst. (1994) 86:368-372. The paper shows the results of the first Phase I study of Adozelesin. The pattern of bone marrow toxicity was subsequently confirmed by other clinical studies.
   Google Scholar
• SHAMDAS GJ, ALBERTS DS, MODIANO M et al: Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anticancer Drugs (1994) 5:10–14.
   Google Scholar
• FOSTER BJ, LORUSSO PM, POPLIN E eta].: Phase I trial of Adozelesin using the treatment schedule of daily x 5 every 3 weeks. Invest New. Drugs. (1996) 13:321–326.
   Google Scholar
• WOLFF I, BENCH K, BEIJNEN JH eta].: Phase I clinical andpharmacokinetic study of Carzelesin (U-80244) given daily for five consecutive days. Clin. Cancer Res. (1996) 2:1717–1723.
   Google Scholar
• PUNT CJA, AWADA A, JANSSENS A et a].: Carzelesin (U-80,244): toxicity patterns and pharmacokinetic data of two Phase I studies [Abstract]. Ann. Oncol (1996) 7(1)30.
   Google Scholar
• SESSA C, PAGANI 0, ZURLO MG eta].: Phase I study of the novel Distamycin derivative tallimustine (FCE 24517). Ann. Oncol (1994) 5:901-907. This Phase I study shows the dose limiting highbone marrow toxicity of Tallimustine which has subsequently been confirmed by further studies.
   Google Scholar
• ABIGERGES D, ARMAND JP, DA COSTA L eta].: Distamycin A derivative, FCE 24517: a Phase I study in solid tumours [Abstract]. Proc. Am. Assoc. Cancer Res. (1993) 34:267.
   Google Scholar
• PUNT CJA, HUMBLET Y, ROCA E eta].: Tallimustine in advanced previously untreated colorectal cancer, a Phase II study. Br. J. Cancer (1996) 73:803–804.
   Google Scholar
• VIALLET J, STEWART D, SHEPHERD F et al.: Tallimustine is inactive in patients with previously treated small cell lung cancer. A Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Lung Cancer (1996) 15:367–373.
   Google Scholar
• GHIELMINI M, BOSSHARD G, CAPOLONGO L et al.: Esti-mation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br. J. Cancer (1997) 75:878-883. The paper shows that the clinical bone marrow toxicity induced by Tallimustine can be reproduced when human bone marrow cells are incubated in culture with concentrations of Tallimustine equivalent to those determined in plasma of patients receiving the MTD of the drug.
   Google Scholar
• POMMIER Y, KOHLHAGEN G, BAILLY C et al: DNA se-quence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumour compound from the Caribbean tuni-cate Ecteinascidia turbinata. Biochemistry (1996) 35:13303–13309.
   PubMed Web of Science ®Google Scholar